FDA approval for the first generation of sensor

27 January 2022

Sunrise V1 has received FDA De Novo approval in the U.S. This is a major milestones for the company and the first step to making the solution available to millions of people suffering from sleep apnea in the US.

Laurent Martinot said this is an exciting time for Sunrise.

"We're thrilled to be working with global thought leaders in the field of sleep to bring this innovative technology to physicians and patients, and to aid in the diagnosis of the millions suffering unnecessarily from sleep apnea in the U.S."